Latest News
Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline
Advance™ technology-enabled solution enables R&D organizations to cut study timelines, deliver cost savings and reduce animal experimentation.
PHILADELPHIA, PA – (BUSINESS WIRE) – January 25, 2024 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ , is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum.
Instem Now Part of ARCHIMED to Further Accelerate Growth and Impact
November 27, 2023 - Healthcare investment specialist ARCHIMED has the expertise, experience, enthusiasm and financial strength to fully back Instem’s ambitions.
Instem Announces New Software Solution to Support Updated Nitrosamines Guidance
September 28, 2023 - New Software Module Introduced to Support the Latest Regulatory-approved Carcinogenic Potency Categorization Approach (CPCA)
Instem Announces Transfer of ToxHub Platform and launch of Centrus®
May 15, 2023 - New powerful technology and data sharing suite provides a range of translational science solutions
Instem Unveils New Additions to its Leading Computational Toxicology Software Suite
November 2, 2022 - New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety
Events
Proud to be Presenting at the FDA 2024 Generic Drug Science and Research Initiatives Public Workshop
May 20 - 21, 2024
FDA, White Oak Campus, Silver Spring, MD
Presentation
'New research in computational toxicology modeling approaches to supplement and expand upon the carcinogenic potency categorization approach to assist generic product development'
Kevin Cross, PhD, VP Regulatory Science, Instem
Solution Areas: In Silico Solutions
Proud to be Presenting at Extractables & Leachables USA
May 21 - 22, 2024
Bethesda, MD
Solution Areas: In Silico Solutions